Data From LigoCyte Pharmaceuticals, Inc.'s Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research
4/28/2010 12:11:28 PM
BETHESDA, Md., April 28 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., a private biopharmaceutical company focused on the development of innovative vaccine products, announced today that results from two Phase I studies of its norovirus virus-like particle (VLP) vaccine candidate were presented today at the 13th Annual Conference on Vaccine Research. Sponsored by the National Foundation of Infectious Diseases, the conference is being held in Bethesda, Maryland, from April 26-28, 2010.
comments powered by